Clinical Utility of beta(3)-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F22%3AA2302J50" target="_blank" >RIV/61988987:17110/22:A2302J50 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000802985400003" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000802985400003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/RRU.S309144" target="_blank" >10.2147/RRU.S309144</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical Utility of beta(3)-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations

Popis výsledku v původním jazyce

This nonsystematic review provides a summary of current evidence on the use of beta(3)-adrenoreceptor agonists (beta(3)-ARAs) for the treatment for lower urinary tract symptoms. Soon after their discovery in 1989, beta(3)-ARs were identified as a predominant adrenoreceptor subtype in the human urinary bladder. Although it is widely believed that beta(3)-ARAs cause detrusor relaxation, the effect on bladder afferent signaling likely plays an important role in their mechanism of action as well. In 2011 and 2012, mirabegron was approved for clinical use in overactive bladder (OAB) patients. Pooled analysis of data from prospective randomized studies on >60,000 OAB patients showed that when compared to placebo, mirabegron was superior with respect to reducing the frequency, number, and severity of urgency episodes, number of incontinence episodes and increasing dry rate, but not in reduction of nocturia episodes. The only side effect showing significantly higher incidence than placebo was nasopharyngitis. Mirabegron is approved for OAB treatment in all age-groups and in pediatric patients with neurogenic bladder. Vibegron is another beta(3)-ARA approved for OAB treatment in the US and Japan. Several large, multicenter, double-blind, randomized trials have documented statistically significant superiority of vibegron over placebo on all efficacy end points. Other beta(3)-ARAs are being developed; however, to date none has been introduced to clinical use. All beta(3)-ARAs provide efficacy similar to anticholinergics. They have a favorable safety profile and are well tolerated. Due to their different mechanisms of action, combination of beta(3)-ARAs with anticholinergic compounds allows for increased efficacy.

Název v anglickém jazyce

Clinical Utility of beta(3)-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations

Popis výsledku anglicky

This nonsystematic review provides a summary of current evidence on the use of beta(3)-adrenoreceptor agonists (beta(3)-ARAs) for the treatment for lower urinary tract symptoms. Soon after their discovery in 1989, beta(3)-ARs were identified as a predominant adrenoreceptor subtype in the human urinary bladder. Although it is widely believed that beta(3)-ARAs cause detrusor relaxation, the effect on bladder afferent signaling likely plays an important role in their mechanism of action as well. In 2011 and 2012, mirabegron was approved for clinical use in overactive bladder (OAB) patients. Pooled analysis of data from prospective randomized studies on >60,000 OAB patients showed that when compared to placebo, mirabegron was superior with respect to reducing the frequency, number, and severity of urgency episodes, number of incontinence episodes and increasing dry rate, but not in reduction of nocturia episodes. The only side effect showing significantly higher incidence than placebo was nasopharyngitis. Mirabegron is approved for OAB treatment in all age-groups and in pediatric patients with neurogenic bladder. Vibegron is another beta(3)-ARA approved for OAB treatment in the US and Japan. Several large, multicenter, double-blind, randomized trials have documented statistically significant superiority of vibegron over placebo on all efficacy end points. Other beta(3)-ARAs are being developed; however, to date none has been introduced to clinical use. All beta(3)-ARAs provide efficacy similar to anticholinergics. They have a favorable safety profile and are well tolerated. Due to their different mechanisms of action, combination of beta(3)-ARAs with anticholinergic compounds allows for increased efficacy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Research and Reports in Urology

ISSN

2253-2447

e-ISSN

—

Svazek periodika

—

Číslo periodika v rámci svazku

2022

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

9

Strana od-do

167-175

Kód UT WoS článku

000802985400003

EID výsledku v databázi Scopus

—